BHA (SALICYLIC ACID)
Commonly Found In
Overview
Salicylic acid is a beta-hydroxy acid (BHA) derived from willow bark that functions as a keratolytic exfoliant, acne treatment, and anti-seborrheic agent in cosmetics and over-the-counter drug products. Unlike alpha-hydroxy acids, its lipophilic (oil-soluble) nature allows it to penetrate into sebum-filled pores, where it dissolves the intercellular cement holding dead skin cells together and helps clear comedones. Clinical evidence supports its efficacy in reducing both non-inflammatory (blackheads, whiteheads) and inflammatory acne lesions at concentrations of 0.5-2%. Salicylic acid is regulated as an OTC drug active in the US and as a restricted cosmetic ingredient in the EU, with specific concentration and application limits due to its keratolytic potency.
Also known as: BHA, Beta Hydroxy Acid, 2-Hydroxybenzoic acid, o-Hydroxybenzoic acid, Salicylate, Orthohydroxybenzoic acid
Key Benefits
Clinical evidence indicates salicylic acid effectively reduces acne lesion countsβincluding blackheads, whiteheads, and inflammatory papulesβthrough its lipid-soluble keratolytic action within pores. Studies suggest it may also help reduce excess sebum, improve skin texture, and modestly address post-acne hyperpigmentation by accelerating surface cell turnover.
Supporting Research
- β’ Zander E & Weisman S (1992). Treatment of acne vulgaris with salicylic acid pads. Clinical Therapeutics, 14(2), 247-253. Demonstrated significant reduction in comedone and papule counts over 12 weeks.
- β’ Shalita AR (1989). Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis, 44(2), 157-161. Confirmed 0.5-2% efficacy and tolerability.
- β’ Arif T (2015). Salicylic acid as a peeling agent: a comprehensive review. Clinical, Cosmetic and Investigational Dermatology, 8, 455-461. Reviewed evidence for keratolytic effects and acne treatment efficacy.
Skin Compatibility Ratings
Comedogenic Rating
Non-comedogenic; clinically used to reduce comedones.
Source: Draelos ZD & DiNardo JC (2006). A re-evaluation of the comedogenicity concept. JAAD, 54(3), 507-512.
Irritancy Rating
Mild-to-moderate irritation potential; dose-dependent. At 0.5-2% leave-on products, stinging, dryness, and peeling can occur, particularly in sensitive skin. Risk increases with higher concentrations or combination with other exfoliants.
Source: CIR Expert Panel (2003). Safety assessment of salicylic acid. International Journal of Toxicology, 22(Suppl 3), 1-108.
Typical Use Concentration
Range
0.5-2%
Optimal
1-2%
2% is the maximum permitted in US OTC acne leave-on products. EU restricts to 0.5% in leave-on face products; 2% permitted in rinse-off products. Higher concentrations (up to 30%) are used only in professional chemical peel settings.
Works Well With / Avoid
Works Well With
Use With Caution
Salicylic acid is most effective at pH 3-4. Do not use with aspirin allergy. Avoid in pregnancy at high concentrations per medical guidance. Not recommended for children under 2 without medical supervision.
Commonly Found In
Global Regulation Summary
Overview of current status across major international markets.
Detailed Regional Status
| Region | Status | Max Conc. | Conditions | Source |
|---|---|---|---|---|
| πͺπΊ EU | Banned | - | - | Official β |
| πΊπΈ USA | Allowed | - | - | Official β |
| π―π΅ Japan | Allowed | - | - | Official β |
| π°π· Korea | Restricted | 0.5% | Not allowed in products for children under 3 (except shampoos and body/hair cleansing products) | Official β |
| π¬π§ UK | Restricted | - | Follows EU regulations (III/98 V/3) | Official β |
π Why Regulations Differ
In the US, salicylic acid is classified as an OTC drug active ingredient for acne treatment at 0.5-2% (FDA monograph). The EU treats it as a restricted cosmetic ingredient under Annex III/98, allowing up to 0.5% in rinse-off face products and 2% in hair products, but prohibiting it in leave-on body products for children. EU restrictions reflect concerns about systemic salicylate absorption, particularly in children. Japan permits salicylic acid in quasi-drug and cosmetic categories. South Korea restricts its use to 0.5% and prohibits it in products for children under 3.
Recent Regulatory Changes
- β’ EU Annex III/98 amendment restricted use in children under 3 and limited leave-on concentrations.
- β’ US FDA OTC Drug Review maintains salicylic acid Category I (safe and effective) for acne at 0.5-2%.
Regulation Analysis
Regional Agreement
Banned in EU but allowed in USA, Japan.
Category Comparison
There are 13 ingredients in the ANTI-SEBORRHEIC category. 100% are banned in at least one major market.
Strictness Ranking
πΏ Natural Sources
Found in willow bark (Salix species, from which it gets its name), meadowsweet, and wintergreen. The precursor salicin occurs naturally in these plants.
π How It's Made
Synthesized through the Kolbe-Schmitt reaction: phenol reacts with sodium hydroxide and carbon dioxide under pressure. Named after Salix (Latin for willow), though modern production is synthetic.
π Uses in Cosmetics
Used at 0.5-2% in exfoliants and acne treatments. Being oil-soluble, it penetrates pores to dissolve sebum and dead skin cells. Commonly found in BHA (beta hydroxy acid) products.
π¬ Other Applications
Used as a pain reliever (aspirin is acetylsalicylic acid), food preservative, and in wart removal treatments.
π‘ Fun Facts
- β’ Hippocrates described willow bark for pain relief around 400 BCE, though the active compound wasn't isolated until 1838
- β’ Aspirin (acetylsalicylic acid) was developed from salicylic acid by Bayer in 1897 to reduce stomach irritation
- β’ It's the only BHA commonly used in skincare, while AHAs include multiple acids (glycolic, lactic, etc.)
Related Skin Concerns
Data Sources
- β’ CIR Expert Panel (2003). Safety assessment of salicylic acid. International Journal of Toxicology, 22(Suppl 3).
- β’ Arif T (2015). Clinical, Cosmetic and Investigational Dermatology, 8, 455-461.
- β’ FDA 21 CFR Part 333 β Acne OTC drug monograph.
- β’ EU Cosmetics Regulation Annex III/98.
- β’ Draelos ZD & DiNardo JC (2006). JAAD, 54(3), 507-512.
Last data verification: 2026-04-12
Related Ingredients
ETHYL LAUROYL ARGINATE HCL
CEDRUS ATLANTICA BARK OIL
CITRUS LIMON PEEL OIL
HYDROLYZED HAIR KERATIN
MYROXYLON PEREIRAE RESIN
PHENOL
Learn More
Frequently Asked Questions
Why is SALICYLIC ACID banned in the EU but allowed in the US?
The EU follows a precautionary principle, banning SALICYLIC ACID under III/98 V/3 due to potential safety concerns. The US FDA has not found sufficient evidence to prohibit its use, allowing it under different safety assessment standards. This reflects differing regulatory philosophies between the two regions.
Why is SALICYLIC ACID banned in the EU but allowed in Japan?
The EU prohibits SALICYLIC ACID (III/98 V/3) based on their strict safety criteria. Japan's Ministry of Health, Labour and Welfare (MHLW) has evaluated the ingredient and permits its use, potentially with different safety data or usage conditions.
What is SALICYLIC ACID used for in cosmetics?
SALICYLIC ACID is primarily used for anti-seborrheic in cosmetic products. It also serves as fragrance, hair conditioning. The ingredient is commonly found in various cosmetic and personal care products.
Which countries regulate SALICYLIC ACID?
SALICYLIC ACID is banned in EU. It has concentration limits or usage restrictions in UK, KR. The ingredient is freely allowed in JP, US.
Are there alternatives to SALICYLIC ACID?
Due to regulatory restrictions on SALICYLIC ACID, cosmetic manufacturers often use alternative ingredients with similar functions. For anti-seborrheic, alternatives may include other approved ingredients in the same category. Consult product labels for specific formulations, and look for products compliant with your region's regulations.
Disclaimer
The information on this website is for educational and informational purposes only and is not intended as medical advice. While we strive for accuracy based on official government databases, cosmetic regulations change frequently. Always consult with a qualified professional or refer to the latest official regulatory documents for compliance. We are not responsible for any actions taken based on the information provided here.